Potapenko ES, Biancardi VC, Zhou Y, Stern JE. Altered astrocyte glutamate transporter regulation of hypothalamic neurosecretory neurons in heart failure rats. Am J Physiol Regul Integr Comp Physiol 303: R291-R300, 2012. First published June 13, 2012; doi:10.1152/ajpregu.00056.2012.-Neurohumoral activation, which includes augmented plasma levels of the neurohormone vasopressin (VP), is a common finding in heart failure (HF) that contributes to morbidity and mortality in this disease. While an increased activation of magnocellular neurosecretory cells (MNCs) and enhanced glutamate function in HF is well documented, the precise underlying mechanisms remain to be elucidated. Here, we combined electrophysiology and protein measurements to determine whether altered glial glutamate transporter function and/or expression occurs in the hypothalamic supraoptic nucleus (SON) during HF. Patch-clamp recordings obtained from MNCs in brain slices show that pharmacological blockade of astrocyte glutamate transporter 1 (GLT1) function [500 M dihydrokainate (DHK)], resulted in a persistent N-methyl-D-aspartate receptor (NMDAR)-mediated inward current (tonic I NMDA) in sham rats, an effect that was significantly smaller in MNCs from HF rats. In addition, we found a diminished GLT1 protein content in plasma membrane (but not cytosolic) fractions of SON punches in HF rats. Conversely, astrocyte GLAST expression was significantly higher in the SON of HF rats, while nonselective blockade of glutamate transport activity (100 M TBOA) evoked an enhanced tonic INMDA activation in HF rats. Steady-state activation of NMDARs by extracellular glutamate levels was diminished during HF. Taken together, these results support a shift in the relative expression and function of two major glial glutamate transporters (from GLT1 to GLAST predominance) during HF. This shift may act as a compensatory mechanism to preserve an adequate basal glutamate uptake level in the face of an enhanced glutamatergic afferent activity in HF rats.
CONGESTIVE HEART FAILURE (HF) is characterized by an increased neurohumoral drive, which involves augmented sympathetic tone, blunted cardiovascular reflexes, and elevated hormonal plasma levels, including vasopressin and ANG II, among others (39, 43, 70) . Chronically elevated plasma VP levels have been reported both in animal models and human patients with HF (16, 19, 51, 61) , being an important factor contributing to altered fluid/electrolyte balance, as well as detrimental myocardial effects (17, 18, 40, 44, 54) .
Vasopressin (VP) [along with the neurohormone oxytocin (OT)], is produced by magnocellular neurosecretory cells (MNCs) located in the hypothalamic supraoptic (SON) and paraventricular nuclei (PVN). VP and OT peptides are then transported to the neurohypophyseal terminals, from where they are released into the circulation, according to the degree and pattern of electrical activity of MNCs (10, 50, 57) . Thus, it is reasonable to speculate that the elevated VP levels in HF result from exacerbated activity of VP neurons. Indeed, a growing body of evidence supports augmented SON and PVN neuronal activation (23, 46, 47, 65, 68) , as well as increased SON/PVN neuronal excitability during HF (23, 68) . Still, the precise underlying mechanisms contributing to increased VP activity in HF remain to be elucidated.
It is well known that MNC firing activity is controlled by the combined action of intrinsic and extrinsic factors (8) . Among the latter, the neurotransmitter glutamate acts as a major excitatory molecule stimulating OT and VP neuronal activity, an action that is largely mediated via activation of NMDA receptors (3, 25, 60, 66) . We have recently shown that in addition to its classical fast synaptic actions, extracellular glutamate can also evoke a tonic, persistent form of excitation, via activation of extrasynaptic NMDA receptors (eNMDARs) (15) . We found this novel glutamate-mediated excitatory modality to potently stimulate SON firing activity, and its strength to be tightly controlled by surrounding astrocytes. Thus, by efficiently clearing glutamate from the extracellular space, astrocyte glutamate transporters (53) restrain the degree of eNMDAR activation, preventing, in turn, overactivation of SON neurons (15) . Recent in vitro and in vivo studies support an enhanced glutamate excitatory action in the SON and PVN of HF rats (29, 31, 34, 49, 69) . However, whether an altered glial regulation of extracellular glutamate levels, and the concomitant activation of eNMDARs, occurs in HF, either as a pathogenic or compensatory mechanism, has not yet been investigated. To address this question, we obtained patchclamp recordings from SON neurons in brain slices obtained from sham and HF rats, as well as immunohistochemical/ Western blot studies to assess protein expression of two of the most predominant astrocytes glutamate transporter isoforms, GLT1 and GLAST. Our results support a diminished GLT1 function/expression in HF rats. This, however, was accompanied by a concomitant increase in GLAST expression and function, leading altogether to a more efficient clearance of ambient glutamate levels, and consequently, diminished tonic activation of NMDARs in HF rats. Thus, the shift in the regulation of extracellular glutamate levels from GLT1 to GLAST transporters may act as a compensatory mechanism in the face of an enhanced glutamatergic afferent activity in HF rats.
MATERIALS AND METHODS

Animals and induction of HF.
Male Wistar rats (150 -180 g) were purchased from Harlan Laboratories (Indianapolis, IN). Rats were housed at room temperature (24 -26°C) in a 12:12-h light-dark cycle room and given free access to food and water. All procedures were carried out in agreement with the Georgia Health Sciences University Institutional Animal Care and Use Committee guidelines. HF was induced by coronary artery ligation as previously described (5, 49) . Briefly, animals were anesthetized with isoflurane 4% and intubated for mechanical ventilation. A left thoracotomy was performed, and the heart was exteriorized. The ligation was placed on the main diagonal branch of the left anterior descending coronary artery. Buprenorphine (Bruprenex C3 0.3 mg/kg sc; Butler Schein/NLS, Dublin, OH) was given immediately after surgery to minimize postsurgical pain. Sham animals underwent the same procedure, but the coronary artery was not occluded. All animals were used 6 to 7 wk after surgery. Transthoracic echocardiography (Vevo 770 system; Visual Sonics, Toronto, Ontario, Canada) was performed 4 wk after surgery under light anesthesia. The left ventricle internal diameter, as well as the left ventricle posterior and anterior walls' diameter, was obtained throughout the cardiac cycle from the short-axis, motion-imaging mode. Automatic calculation using the parameters measured was obtained for ejection fraction and fractional shortening. Representative echocardiography images are shown in Fig. 1 , and mean cardiac function values obtained from sham and HF rats are summarized in Table 1 .
Hypothalamic slice preparation. Hypothalamic brain slices were prepared according to methods previously described (49, 59) . Briefly, rats were deeply anesthetized with pentobarbital sodium (80 mg/kg ip) and perfused through the heart with an ice-cold sucrose solution [containing in mM: 200 sucrose, 2.5 KCl, 3 MgSO 4, 26 NaHCO3, 1.25 NaH 2PO4, 20 D-glucose, 0.4 ascorbic acid, 1 CaCl2, and 2 pyruvic acid (290 -310 mosmol/l)]. Rats were then quickly decapitated, brains were dissected out, and coronal slices were cut (300 m thick) using a vibroslicer (D.S.K. Microslicer, Ted Pella, Redding, CA). An oxygenated ice-cold artificial cerebrospinal fluid (ACSF) was used during slicing (containing in mM: 119 NaCl, 2.5 KCl, 1 MgSO4, 26 NaHCO3, 1.25 NaH2PO4, 20 D-glucose, 0.4 ascorbic acid, 2 CaCl2, and 2 pyruvic acid; at pH 7.4; 290 -310 mosmol/l). Slices were placed in a holding chamber containing ACSF and kept at room temperature until used.
Patch-clamp electrophysiology. Slices were bathed with solutions (ϳ2.0 ml/min) that were continuously bubbled with 95% O2-5% CO2 and maintained at 32°C. Thin-walled (1.5 mm O.D., 1.17 mm I.D.) borosilicate glass (G150TF-3; Warner Instruments, Sarasota, FL) was used to pull patch pipettes (3-4 M⍀) on a horizontal Flaming/Brown micropipette puller (P-97; Sutter Instruments, Novato, CA). The internal solution contained (in mM): 140 potassium gluconate, 0.2 EGTA, 10 HEPES, 10 KCl, 0.9 MgCl2, 4 MgATP, 0.3 NaGTP, and 20 phosphocreatine (Na ϩ ); pH 7.2-7.3. For voltage-clamp recordings, a low Mg 2ϩ ACSF (20 M MgSO4,) was used to facilitate measurements of NMDA-mediated currents. Recordings were obtained with an Axopatch 200B amplifier (Axon Instruments, Foster City, CA) from SON/PVN neurons using infrared differential interference contrast videomicroscopy. The voltage-output was digitized at 16-bit resolution, 10 kHz, and were filtered at 2 kHz (Digidata 1320A; Axon Instruments). Data were discarded if the series resistance were not stable throughout the entire recording (Ͼ20% change), or if neuronal input resistance were lower than 350 M⍀ at the beginning of the recording (49, 59 ). The NMDA receptor-mediated tonic current (tonic INMDA) in SON neurons (15) was assessed by measuring changes in holding current (Iholding) and root mean square (RMS) baseline noise levels following either bath application of glutamate receptor blockers or after blockade of glutamate transporter function. The mean tonic INMDA amplitude was calculated as the difference in the holding current measured as the average of a 2-min segment of steady-state baseline obtained before and after a 5-min application of blockers (15) . The tonic INMDA current density was determined by dividing the current amplitude by the cell capacitance, obtained by integrating the area under the transient capacitive phase of a 5-mV depolarizing step pulse, in voltage-clamp mode. RMS noise was measured using Pclamp software within seven different 100-ms segments of traces lacking PSCs, and values were averaged. D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), and dihydrokainic acid (DHK) were purchased from Ascent Scientific (Princeton, NJ). All other drugs were purchased from Sigma-Aldrich (St. Louis, MO).
Immunohistochemistry and imaging analysis. Standard immunohistochemistry was performed as previously described (4) . Briefly, rats were perfused transcardially with 150 ml of 0.01 M PBS followed by 350 ml of 4% paraformaldehyde (PFD). Brains were dissected out, postfixed overnight in 4% PFD, and then cryoprotected in 0.01 M PBS containing 30% sucrose for 3 days at 4°C. Sequential 30-m hypothalamic coronal sections were collected and subsequently blocked for unspecific sites in 10% horse serum. Sections were then incubated in a mixture of primary antibodies against EAAT2 glutamate transporter (anti-rabbit GLT1, 1:1,000 for 48 h; Abcam, Cambridge, MA); glial fibrillary protein [anti-mouse glial fibrillary acidic protein (GFAP), 1:2,000 for 24 h; Chemicon, Temecula, CA] and (Arg8)-vasopressin (anti-guinea pig VP 1:50,000 for 24 h; Bachem, Torrance, CA) or a mixture of EAAT1 glutamate transporter (anti-rabbit GLAST, 1:2,000 for 48 h; Abcam, MA) and anti-mouse GFAP, as described previously. Immunoreactivity was visualized by secondary reaction with anti-rabbit Cy3 (1:250); anti-mouse Alexa Fluor 647 (1:50) and anti-guinea pig FITC (1:250) for 4 h. Blocking agent and all antibodies were diluted in PBS 0.01 M containing 0.1% Triton X-100 and 0.04% NaN 3. All secondary antibodies were purchased from Jackson ImmunoResearch Laboratories (Bar Harbor, ME). Preabsorption controls for EAAT2 antibody were performed using a five-fold molar excess (relative to IgG concentration) of synthetic antigen (Ab 41752; Abcam, Cambridge, MA), as previously described (58) .
Acquisition and quantification of immunofluorescent images were done as previously described (4) . A Zeiss LSM 510 confocal scanning microscope (Carl Zeiss, Oberkochen, Germany) was used to obtain 15 consecutive optical focal planes (30 m thick, 2-m interval) at various rostrocaudal levels of the SON. Images from HF and sham groups were digitized with identical acquisition settings. For quantification, a projection image of the sections was generated, and imaging analysis was performed using Image J software (NIH). The SON nucleus was manually traced using VP or GFAP immunoreactivity as an anatomical landmark. Subsequently, background fluorescence was subtracted from the images from areas lacking immunoreactive signal. The density of GLT1 and GFAP thresholded signal within the traced nucleus was obtained from the different channels using the same demarcated area and expressed as a percentage of threshold area (i.e., a percentage of total area containing thresholded immunoreactive signal). The mean immunoreactivity intensity was also obtained from the same regions and expressed as arbitrary units (4). Likewise, colocalization was calculated from both images superimposed within the same region previously measured and also expressed as the percentage of threshold area. Algorithms were provided by Image J software. A mean value of all sampled sections was calculated, and then values per animal were used for statistical analysis.
Western blots. Brains from sham and HF animals (n ϭ 4 each group) were dissected, fast frozen in isopentane Ϫ35°C for 30 s, and transferred to a cryostat. The SON was punched out from 300-m hypothalamic slices (three sequential slices/rat) using a micropunch (Ted Pella, Redding, CA), and immediately frozen on liquid nitrogen. Membrane and cytosolic fractions were extracted from SON punches, according to methods described previously (38) . Briefly, samples were homogenized in 40-l ice-cold lysis buffer (RIPA buffer added PMSF; a cocktail of protease inhibitors and Na3VO4), extracted on ice for 1 h and then centrifuged at 4°C 1,000 g for 10 min for rough partition between cytosolic and membrane fractions. The supernatant was collected, recentrifuged at 16,000 g for 15 min to isolate any contaminating pellet materials and recollected as cytosolic fraction.
The initial pellet was resuspended in 10-l cell lysis buffer containing 1% Triton X-100, extracted on ice for 1 h, centrifuged at 4°C 16,000 g for 15 min, and the supernatant was collected as a membrane fraction. The Bradford method was used to measure protein concentration from each fraction using BSA as a standard; 7.5 g of total protein from each fraction for sham and HF were separated on an SDS-PAGE 10% polyacrilamide gel and electrophoretically transferred to a nitrocellulose membrane. The nonspecific sites of the membrane were blocked with 5% nonfat dry milk in Tris-buffered saline solution with Tween 0.1% (TBS-T) for 1 h. The membranes were then incubated overnight at 4°C with the primary rabbit polyclonal antibody raised against EAAT2 (GLT, 1:500; Abcam) diluted in 5% nonfat milk in TBS-T. The membrane was washed and subsequently incubated with an anti-rabbit horseradish peroxidase secondary antibody. A chemiluminescent assay kit (ChemiGlow; Alpha Innotech, Santa Clara, CA) was used to detect immunoreactivity, and the intensity of all bands was estimated by densitometry analysis (Alpha View Software-Proteinsimple, Santa Clara, CA). All densitometry measurements were normalized using an antibody against ␤-actin (1:30,000; Sigma-Aldrich, St. Louis, MO) as a loading control and expressed as unit of change.
Statistical analysis. All values are expressed as means Ϯ SE. Student's paired t-test was used to compare the effects of a drug treatment on tonic I NMDA. Between-group differences (e.g., sham vs. HF) were compared using unpaired t-tests or ANOVA, as indicated followed by Bonferroni post hoc tests. Differences were considered statistically significant at P Ͻ 0.05, and n refers to the number of cells. All statistical analyses were conducted using GraphPad Prism (GraphPad Software, San Diego, CA).
RESULTS
Representative echocardiography images obtained from a total of 25 sham and 18 HF rats are shown in Fig. 1 , and mean cardiac function values obtained are summarized in Table 1 . Compared with sham rats, ligated rats showed a significant increased left ventricle internal dimension throughout the cardiac cycle, a decreased percentage of ejection fraction, and a decreased percentage fractional shortening (P Ͻ 0.0001 in all cases). Patch-clamp electrophysiological recordings were obtained from a total of 87 SON MNCs obtained from sham (n ϭ 48 MNCs from 16 rats) and HF rats (n ϭ 39 MNCs from 10 rats).
Blunted glial GLT1 transporter function and expression in the SON of HF rats. Blockade of the astrocyte glutamate transporter GLT1 by bath-applied dihydrokainate (DHK, 500 M) resulted in a sustained inward shift in I holding in SON neurons ( Fig. 2A) , as well as an increase in basal RMS noise level (basal: 5.9 Ϯ 0.9 pA; DHK: 9.5 Ϯ 1.4 pA; P Ͻ 0.01), due to increased stochastic channel activity (52) . The DHK-evoked shift in I holding was significantly and largely blocked when slices were preincubated with an NMDA receptor blocker (100 M AP5, n ϭ 6, P Ͻ 0.001) but not with an AMPA receptor blocker (10 M DNQX, n ϭ 5) (Fig. 2B) . As we recently demonstrated, this current (termed also tonic I NMDA ) is mediated by activation of extrasynaptic NMDA receptors by extracellular glutamate (15) .
The magnitude of the DHK-evoked tonic I NMDA was significantly smaller in SON neurons recorded in HF, compared with sham rats (P Ͻ 0.01). Representative examples and summary data are shown in Fig. 3 . Similarly, a blunted DHK-evoked change in RMS was also observed in HF rats (sham: ⌬3.6 Ϯ 0.9 pA; HF: ⌬1.6 Ϯ 0.3, P Ͻ 0.05). To rule out that these effects were not secondary to potential changes in neuronal size in HF rats, we measured neuronal cell capacitance and compared current densities between groups. SON cell capacitance was similar between sham and HF rats. Accordingly, the DHK-evoked tonic I NMDA current density was still significantly smaller in SON from HF, compared with sham rats (P Ͻ 0.01, Fig. 3B) .
To determine whether a diminished GLT1 protein expression contributed to the observed blunted DHK-evoked tonic I NMDA in HF rats, we measured GLT1 along with GFAP immunoreactivites in the SON of sham and HF rats (n ϭ 4 rats in each group). Representative examples are shown in Fig. 4A-F . GLT1 immunoreactivity was localized in neuropilar elements, and in many cases, in close apposition to VP neuronal somata. As expected, we found a certain degree of colocalization between GLT1 and GFAP profiles, but not with VGLUT2, a marker of glutamatergic presynaptic terminals (Fig. 4, G and H) , supporting a glial, rather than neuronal, localization of GLT1 in the SON. Preabsorption of the GLT1 antibody with the respective antigen protein resulted in complete absence of staining (not shown). No differences in GLT1, nor GFAP SON immunoreactivity densities or mean intensities, or in their degree of colocalization, were observed between sham and HF rats (Fig.  4, I and J) . Given however, that the approach used did not distinguish membrane from cytosolic GLT1 distribution and that an altered trafficking of GLT1 to and from the surface membrane has been reported in several brain disease conditions (9, 67), we further investigated GLT1 protein expression by performing Western blot analyses of GLT1 protein in membrane and cytosolic fractions of SON punches. As shown in Fig. 4K , while GLT1 content in cytosolic fractions was similar between sham and HF rats, a significantly lower con- D-F) , respectively. G: colocalization diagram from merged GLT1 and GFAP from the area delineated in E (red is GLT1, green is GFAP, and white represents the colocalized signal between both). H: confocal photomicrograph showing no colocalization between GLT1 (red) and VGLUT-positive boutons (green). I, J: summary data showing no differences in GLT1, GFAP, or GLT1-GFAP colocalization immunoreactivity density (I) or intensity (J) in HF rats compared with sham rats. K: representative Western blot bands for GLT1 protein levels on SON cytosolic and membrane fractions in a sham and HF rat. The summary data showed decreased membrane, but not cytosolic, GLT1 protein levels in HF compared with sham rats. OT: optic tract. *P Ͻ 0.05 vs. sham. n ϭ 4 in each group. Scale bars: 50 m (C, F, and G) and 10 m (H). tent was observed in SON membrane fractions in HF compared with sham rats (P Ͻ 0.02).
Tonic persistent activation of eNMDARs by ambient glutamate levels is diminished in SON neurons from HF rats.
We have shown that the magnitude of the basal tonic I NMDA , which results from activation by extracellular ambient glutamate levels under glial control, can be monitored as an outward shift in the holding current following NMDAR blockade (15) . Thus, we used this approach to determine whether the blunted GLT1 expression/function described above resulted in an increased activation of basal tonic I NMDA . As we previously reported (15) , bath application of AP5 (100 M) induced a sustained outward shift in I holding in SON neurons. However, we unexpectedly found the AP5 effect to be significantly smaller in SON neurons from HF compared with sham rats (sham: ⌬24.3 Ϯ 8.24 pA; HF: ⌬6.8 Ϯ 3.4 pA, P Ͻ 0.05, n ϭ 11/group) (Fig. 5, A and B) . Similarly, a smaller AP5-evoked change in RMS was also observed in HF rats (sham: ⌬4.5 Ϯ 0.7 pA; HF: ⌬2.4 Ϯ 0.3 pA, P Ͻ 0.02, n ϭ 11/group). These results indicate that despite the blunted contribution of GLT1 to glutamate clearance, there is an overall diminished basal tonic activation of I NMDA in HF rats.
Enhanced glial GLAST transporter function and expression in SON of HF rats. Our findings showing blunted GLT1 activity/expression along with a diminished tonic activation of I NMDA suggests that an alternative glutamate transport mechanism, most likely GLAST, may be compensating in the clearance of extracellular glutamate for the compromised GLT1 activity during HF. It has been recently shown that a diminished GLT1 function/expression can lead to a compensatory response involving an increased function/expression of the alternative major glutamate transporter in the central nervous system, GLAST (55) . To determine whether this was the case in HF rats, we measured GLAST immunoreactivity in the SON of sham and HF rats (n ϭ 4 and 3 rats, respectively). Representative examples are shown in Fig. 6 , A-D. Similar to GLT1, GLAST immunoreactivity displayed a glial-like pattern, with a predominant neuropilar distribution surrounding somata of large magnocellular neurons. Colocalization with GFAP, but not VGLUT2, immunoreactivities, was observed (Fig. 6, E and F) . Compared with sham rats, GLAST immunoreactivity, density, mean intensity, as well as its colocalization with the glial marker GFAP, were significantly enhanced in HF rats (P Ͻ 0.01) (Fig. 6, G and H) .
We then assessed whether the enhanced GLAST protein expression in the SON of HF rats translated into a more predominant functional contribution of this transporter to glutamate clearance. We attempted first to use a recently developed selective GLAST blocker compound, UCPH-101 (28) . Unfortunately, however, in our hands, this compound was only soluble at high DMSO concentrations, which resulted per se in a change in holding current (not shown). Thus, as an alternative approach, we tested the effects of the nonselective glutamate transporter blocker DL-threo-␤-benzyloxyaspartic acid (TBOA). We found that similar to DHK, bath application of TBOA (100 M) induced a sustained inward shift in I holding . This effect, however, was significantly larger in SON neurons from HF compared with sham rats (sham: ⌬267.8 Ϯ 33.1 pA; HF: ⌬576.3 Ϯ 136.0, P Ͻ 0.02, n ϭ 8 and 6, respectively, Fig. 6,  I and J). Similar differences were obtained when data were expressed as current density (sham: ⌬9.2 Ϯ 3.8 pA/pF; HF: ⌬15.7 Ϯ 6.7 pA/pF, P Ͻ 0.05). Similarly, a larger TBOAevoked change in RMS noise level was also observed in HF rats (sham: ⌬0.3 Ϯ 5.9 pA; HF: ⌬18.6 Ϯ 5.1, P Ͻ 0.001).
Finally, the fact that we observed opposing changes in tonic I NMDA following selective and nonselective glutamate transporter blockade argues against a contribution of altered NMDAR function and expression per se to the reported changes in I NMDA during HF. Nonetheless, given that previous reports demonstrated an altered expression of NR1 NMDAR subunits in PVN neurons of HF rats (34), we tested for this possibility by directly activating NMDARs via bath application of the agonist NMDA (30 M), with the caveat that while this approach preferentially activates extrasynaptic NMDARs, synaptic receptors would also be activated. As shown in Fig. 7 , no differences in evoked NMDA current or current density were observed between SON neurons from sham or HF rats (n ϭ 26 and 22, respectively). 
DISCUSSION
An augmented neuronal activation, along with a concomitant increase in firing activity (23, 46, 47, 65, 68) , has been proposed to contribute to neurohumoral activation in HF rats. While an enhanced glutamate function has been demonstrated in the SON/ PVN of HF rats (29, 31, 34, 49, 69) , the precise mechanisms underlying regulation of glutamate function in HF remain unknown. We have recently demonstrated the presence of a novel glutamate excitatory modality in SON neurons (i.e., tonic I NMDA ), which is mediated by activation of eNMDARs by extracellular glutamate. We have also shown that by tightly regulating extracellular glutamate levels, astrocyte glutamate transporters influence the strength of tonic I NMDA (15) . In this study, we aimed to determine whether changes in astrocyte glutamate transporter function and/or expression occur in the SON of HF rats, contributing, in turn, to altered glutamate excitatory actions in HF rats.
Glutamate transporters, particularly the astrocytic GLT1 and GLAST isoforms, constitute the major mechanism for glutamate clearance and maintenance of low ambient glutamate levels in the central nervous system (11, 53) . As shown in Figs. 2 and 3 in this article, selective blockade of GLT1 function via bath application of DHK induced a persistent inward current in SON neurons, mediated by activation of NMDA, but not AMPA receptors (tonic I NMDA ). As we recently reported, tonic I NMDA is mediated by activation of extrasynaptic NMDARs, which strongly stimulate SON firing activity (15) . Taken together, these results indicate that under basal conditions, glial GLT1 transporters actively maintain extracellular glutamate at relatively low levels, restraining, in turn, the degree of extrasynaptic NMDAR activation, and its excitatory effect on SON neuronal activity.
Here, we found that the enhancement of tonic I NMDA following glial GLT1 blockade was diminished in SON MNCs from HF rats, supporting a blunted contribution of GLT1 function to extracellular glutamate clearance during HF. To determine whether this was associated with a diminished GLT1 protein expression, we performed immunohistochemistry and Western blot analyses. Using conventional immunohistochemistry, we did not observe differences in overall GLT1 immunoreactivity between sham and HF rats. However, it is still possible that changes in GLT1 expression were below detectable levels of this technique, or alternatively, that changes in GLT1 expression were restricted to a specific cell compartment (e.g., surface plasma membrane), which conventional immunohistochemistry would fail to discriminate. This later option was indeed confirmed by our Western blot studies, which revealed a diminished GLT1 expression in membrane, but not cytoplasmic fractions in SON punches from HF rats. A selective decrease in protein expression at the surface membrane could reflect an altered trafficking of GLT1 to and from the surface membrane during HF. Trafficking and translocation are critical steps for proper transport activity, which are amenable to modulation by a variety of mechanisms, particularly protein kinases (2, 6, 20, 33) . Importantly, reactive oxygen species (ROS) have been shown to prevent GLT1 trafficking, diminishing, in turn, GLT1 activity (38, 63, 64) . This is particularly relevant to this study, given the well-documented increased oxidative stress in the hypothalamus of HF rats and its critical contribution to neurohumoral activation in this disease (22, 26, 27, 36, 37) . Thus, future studies evaluating the role of ROS in altered GLT1 function and expression during HF are warranted.
Similar to what we recently reported in SON neurons of water-deprived rats (15) [see, however, (30)], we hypothesized that a diminished GLT1 activity in HF rats would result in an enhanced activation of tonic I NMDA in SON neurons (due to excess of extracellular glutamate), contributing, in turn, to increased neuronal excitability in HF rats. Our results with the NMDAR blocker AP5, however, support the opposite phenomenon. AP5 under basal conditions in sham rats resulted in an outward shift in I holding , reflecting the tonic activation of NMDARs by extracellular glutamate levels (15, 32) . Unexpectedly, we found a blunted AP5 effect in SON neurons from HF rats, suggesting lower basal levels of extracellular glutamate, possibly due to a more efficient clearance mechanism during this condition.
It was recently shown that blockade of GLT1 in the striatum evokes a transient compensatory increase in GLAST activity, resulting in an overall increase in glutamate uptake (55) . This response was proposed to provide an endogenous defense mechanism against excitotoxicity to the nigrostriatal pathway (55). Our results showing an increased GLAST expression in the SON of HF rats, along with a larger TBOA-evoked activation of tonic I NMDA support a compensatory enhancement of GLAST participation in extracellular glutamate clearance in the SON of HF rats. Thus, one possible scenario to consider is that in the initial stages of HF, an enhanced glutamate afferent activity, along with a blunted GLT1 expression and activity, results in an excess of extracellular glutamate levels (29, 31, 34) , which then triggers a compensatory increase in GLAST expression and activity, in an attempt to maintain extracellular glutamate levels within normal ranges. In this sense, astrocyte GLAST activity has been shown to be enhanced in response to increases in glutamate levels (14) . Future studies evaluating the time-course of changes in GLT1/ GLAST expression and activity during the progress of the HF syndrome would be necessary to more conclusively support this hypothesis. Finally, it is important to consider that a limitation of these studies is that extracellular glutamate levels in vitro may not necessarily reflect those in vivo, in which the activity of all glutamate afferent inputs is preserved. Thus, future whole animal studies would be needed to confirm the in vitro findings reported in our study.
In summary, results from this study support a shift in the relative expression and function of two major glial glutamate transporters (from GLT1 to GLAST predominance) during HF. Despite these changes, basal steady-state activation of eNMDARs by extracellular glutamate, rather than being exacerbated, was actually found to be diminished. Thus, our studies suggest that compromise in one of the major glutamate uptake mechanisms (GLT1) in heart failure leads to the compensatory enhancement of an alternative one (GLAST) in order to preserve an adequate basal glutamate uptake level.
Perspectives and Significance
Given the clinical relevance of neurohumoral activation in HF, there is a great deal of interest in elucidating its underlying mechanisms. While a growing body of evidence supports elevated excitatory glutamate function as a pivotal pathophysiological finding in HF, the precise mechanisms contributing to such elevated excitatory effects, as well as potential compensatory cellular and network responses, remain unclear.
Astrocytes have emerged in recent years as critical players in the regulation of neuronal and synaptic function in the central nervous system (1, 41) . Moreover, an abnormal astrocyte function, including altered GLT1 modulation of extracellular glutamate levels, has been demonstrated in various neurological conditions, including Alzheimer's disease, stroke, and amyotrophic lateral sclerosis (12, 35, 56) . Still, whether an altered astrocyte function also contributes to cardiovascular related disorders, particularly those displaying elevated neurohumoral activation, is still unknown.
The magnocellular neurosecretory system provides an ideal model to address this problem. It is a relatively simple, wellcharacterized system that displays a unique and highly plastic neuroglial microenvironment (24, 62) . A growing body of evidence supports a major role of astrocytes in the regulation of SON/PVN neuronal function, via a variety of mechanisms, including release of neuroactive substances, such as ATP (21), taurine (13), D-serine (45) , and nitric oxide (5), as well as via the activity of neurotransmitter transporters. Thus, glial GLT1 have been shown to strongly influence the efficacy of both metabotropic glutamate receptors (7, 42, 48) , as well as extrasynaptic NMDA receptor activation (15) . Results from the present study provide evidence for a change in glial regulation of glutamate function during HF, which involves a shift in the expression of different glutamate transporters, as well as in their relative contribution to glutamate uptake. Future studies evaluating the time course of such changes are necessary to determine their overall contribution to neurohumoral activation, either as a pathogenic or compensatory mechanism.
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